|
|
The
Pharma & Biotech market has generated very
attractive returns for many investors, but at the
same time has produced losses to other investors.
The sector contains a large number of extra-high
risk companies, many of which are founded on weak
foundations and pursuing projects that are unlikely
to either reach the market or to be seen as
attractive opportunities by big pharma companies for
commercialisation. The professional large investors
recently focus much more on mature companies with
products and a pipeline.
|
|
Small, private companies may be able to
progress development of their compounds or
technologies up to a point, but are very
unlikely to be able to commercialise
pharmaceutical products on their own on a
worldwide basis, as they will not be able to
set up the infrastructure for marketing and
distribution. As a result, the vast
majority of biotech companies will need
corporate deals with pharma companies that
have the means to commercialise on a large
scale and around the world. Unfortunately
many companies do not “focus on customer
needs”, in terms of recognising that
actually big-pharma (and medium-size pharma
!) is the end-customer, not the stock
markets. Pharma deals are crucial to
biotech companies and investors CAN play key
role and CAN drive corporate deals, much
like they drive IPOs.
|
|
|
In addition, DyoDelta Biosciences can assist
investors' portfolio companies deliver pharma deals that may
facilitate exit and provide validation for the public
markets. Investing in the pharma and biotech sector is
accompanied by high risk. Expert industry knowledge can
help to make the right decisions.
|
|
|
